Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Sosei Group is not ready to give up on its fibromyalgia candidate AD 337 after a Phase II study failed to meet its primary endpoint, the firm announced Sept. 18

You may also be interested in...



Sosei’s Cancer Breakthrough Pain Drug Moves Step Closer To Market

TOKYO - Sosei has started Phase III studies in Europe for its novel fentanyl sublingual spray AD 923, an opiod analgesic used for the treatment of cancer breakthrough pain, the Tokyo-based biopharmaceutical company announced Feb. 12

Sosei’s Cancer Breakthrough Pain Drug Moves Step Closer To Market

TOKYO - Sosei has started Phase III studies in Europe for its novel fentanyl sublingual spray AD 923, an opiod analgesic used for the treatment of cancer breakthrough pain, the Tokyo-based biopharmaceutical company announced Feb. 12

Cymbalta Fibromyalgia sNDA Could Make Lilly Product Lyrica’s First Competitor

Patients treated with Cymbalta show greater reduction in pain compared to placebo in a six-month pivotal trial, Lilly reports.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

SC066536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By